Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
121 hedge funds and large institutions have $1.52B invested in Spark Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 26 reducing their positions, and 17 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 26
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
23% more capital invested
Capital invested by funds: $1.24B → $1.52B (+$284M)
5% more funds holding
Funds holding: 115 → 121 (+6)
8% more call options, than puts
Call options by funds: $5.22M | Put options by funds: $4.84M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$27.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.9M |
| 5 |
Goldman Sachs
New York
|
+$8.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.9M |
| 2 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$6.89M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.99M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.71M |
| 5 |
CC
Casdin Capital
New York
|
-$3.98M |
ONCE Hedge Fund Activity: Q3 2016 in Review
121 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q3 2016, worth a combined $1.52B — up 23% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ONCE positions and 17 closed out — a net gain of 7 holders — while 53 added to existing stakes and 26 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $27.2M. The largest seller was Millennium Management, exiting entirely with an estimated $15.9M sold.
- 121 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q3 2016, up from 115 in Q2 2016.
- Funds reported $1.52B of Spark Therapeutics, Inc. Common Stock stock for Q3 2016, up 23% quarter-over-quarter.
- 24 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q3 2016 and 17 closed out, a net change of +7 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q3 2016 was Victory Capital Management, an estimated $27.2M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q3 2016 was Millennium Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2016.